Greenwich LifeSciences, Inc.
GLSI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $146 | $135 | $196 | $315 |
| - Cash | $4 | $7 | $13 | $27 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $142 | $128 | $183 | $288 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$16 | -$9 | -$8 | -$5 |
| % Margin | – | – | – | – |
| Net Income | -$16 | -$9 | -$8 | -$5 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.21 | -0.69 | -0.61 | -0.35 |
| % Growth | -75.4% | -13.1% | -74.3% | – |
| Operating Cash Flow | -$7 | -$6 | -$6 | -$4 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$7 | -$6 | -$6 | -$4 |